Thrombotic Thrombocytopenic Purpura (TTP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Thrombotic Thrombocytopenic Purpura (TTP) Market Outlook

Thelansis’s “Thrombotic Thrombocytopenic Purpura (TTP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Thrombotic Thrombocytopenic Purpura treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Thrombotic Thrombocytopenic Purpura (TTP) Overview

Thrombotic thrombocytopenic purpura (TTP) is a form of microangiopathic hemolytic anemia characterized by the classic pentad of symptoms: fever, thrombocytopenia, hemolytic anemia, renal dysfunction, and neurologic dysfunction. TTP arises from a deficiency or absence of ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif member 13), either congenital or acquired. Reduced levels of ADAMTS13 lead to the formation of microthrombi, resulting in ischemic damage to various organs. ADAMTS13 cannot effectively inhibit the large multimer von Willebrand factor (VWF), crucial for preventing spontaneous coagulation. Differential diagnoses encompass other thrombotic microangiopathies (TMAs), such as hemolytic uremic syndrome and TMA, secondary to factors like transplantation, chemotherapy, drugs, HIV/AIDS, and HELLP syndrome. Other conditions include catastrophic antiphospholipid syndrome, severe sepsis, vitamin B12 deficiency, malignant hypertension, and disseminated intravascular coagulopathy. Due to the severity of TTP and the risk of sudden organ failure, it is advisable to manage patients in intensive care units until their platelet count returns to normal. The current standard treatment regimen involves plasma exchange to replenish active ADAMTS13 from donor plasma (and, to a lesser extent, remove anti-ADAMTS13 antibodies and pro-aggregate substances). Immunosuppressive therapies like glucocorticoids and rituximab are administered to prevent the production of ADAMTS13 antibodies, and caplacizumab, a nanobody targeting von Willebrand factor (VWF), is employed to expedite platelet count recovery and prevent adverse outcomes. Without intervention, the mortality rate for thrombotic thrombocytopenic purpura is 90%. However, early treatment involving plasma exchange and corticosteroids reduces mortality by 15%. The longer a patient delays seeking treatment, the greater the likelihood of experiencing unfavorable outcomes.

• In the United States, the annual incidence of TTP ranges from 3 to 11 cases per million people.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: